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conventional radiotherapy techniques. It has been shown that 
the dosimetrical benefit of IMRT translated into a clinically 
significant reduction in lower gastrointestinal toxicity 
compared with three-field conventional radiotherapy. MRI-
linacs and proton therapy are likely to broaden the 
therapeutic window further in the near future. Prone 
positioning on a bellyboard reduces small bowel toxicity by 
pushing away the small bowel loops from the high dose 
region. Image-guided radiotherapy allows for an accurate 
definition, localization and monitoring of tumor position, size 
and shape before and during treatment and may help to 
reduce set-up margins.  
Small randomized controlled trials have shown that the 
administration of several agents might have a beneficial 
effect for the prevention of acute (e.g. intrarectal 
amifostine, oral sulfasalazine and balsalazide) and/or late-
onset radiation-induced toxicity (intrarectal beclomethasone 
and oral probiotics). Once severe toxicity develops, total 
replacement of the diet with elemental formula may be 
appropriate. Probiotics influence the bacterial microflora and 
seem promising in reducing the incidence and severity of 
radiation-induced diarrhea. Currently there is insufficient 
evidence for cytoprotective and anti-inflammatory drugs in 
the management of radiation-induced toxicity. Future 
challenges lie in the prediction of treatment-related toxicity, 
which might be a promising step towards an individualized 
risk-adapted treatment.  
 
103 
Lessons from translational research in EORTC glioma trials 
M. E Hegi 
Laboratory of Brain Tumor Biology and Genetics  
Neurosurgery & Neuroscience Research Center 
Department of Clinical Neurosciences 
University Hospital Lausanne, lausanne Switzerland 
 
Glioblastoma (GBM) is the most common and most malignant 
primary brain tumor in adults with a dismal prognosis of 15 to 
18 months and few therapeutic options. GBM are notorious 
for their resistance to therapies, likely due to a plethora of 
genetic and epigenetic alterations affecting multiple cancer 
relevant pathways conferring enhanced adaptive plasticity to 
tumor cells. The addition of concomitant and adjuvant 
temozolomide to radiotherapy has been introduced 10 years 
ago based on the pivotal EORTC-NCIC trial. At the same time, 
the predictive value of promoter methylation of the repair 
gene MGMT for benefit from the alkylating agent 
temozolomide has been established. Despite efforts in 
developing targeted agents this combination therapy is still 
the current the standard of care. Clinical trials have used the 
combination therapy as backbone and added new drugs, 
immunotherapies, or use of devices. Or, in a second strategy, 
patients were selected according to their MGMT status. 
MGMT unmethylated patients who basically do not profit 
from alkylating agent therapy can be entered into trials 
omitting temozolomide. This allows avoiding unnecessary 
toxicity, thereby enhancing chances for new drugs and 
providing new options for patients with a particularly bad 
prognosis. Advances of molecular techniques have led to 
discovery of new genetic and epigenetic alterations with 
prognostic and predictive value that have changed tumor 
classification, in particular in lower grade gliomas. This 
emphasizes the importance of collection of tumor tissue 
within clinical trials to test respective markers that need to 
be taken into account when analyzing completed trials or 
devising new strategies for clinical trials. Druggable 
mutations are usually only present in a relatively small subset 
of patients, a fact that is observed across tumor types. 
Therefore, in a new strategy the EORTC has launched the 
SPECTA program – allowing for efficient biomarker screening 
across all tumor types for improving access to molecularly 
driven and transversal clinical trials. SPECTAbrain will open 
in January. 
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The growth and development of solid tumours requires an 
adequate supply of oxygen and nutrients. Initially this is 
obtained from the vascular supply of the normal tissue in 
which the tumour arises. However, the demands of the 
growing tumour mass soon exceed the supply from this source 
and further growth is only possible if the tumour forms its 
own blood supply from the host vessels via the process of 
angiogenesis. This significance of the tumour neo-vasculature 
makes it an excellent target and two approaches have now 
emerged. These are the more popular use of drugs that 
inhibit the angiogenesis process and the less popular use of 
agents that disrupt the already established tumour 
vasculature. This latter approach actually has a much longer 
history than angiogenesis inhibitors. Indeed, the first vascular 
disrupting agent (VDA) investigated as an anti-tumour agent 
was colchicine back in the 1930s. Although it was shown to 
possess significant anti-tumour activity in both pre-clinical 
and clinical studies, it was also found to have substantial 
systemic toxicity. Later agents with VDA activity were also 
very toxic. This changed in the 1980s when combretastatin A-
4 phosphate (fosbretabulin) was developed from products 
isolated from the bark of the African Bush Willow and found 
to have anti-tumour activity at doses well below those that 
caused systemic toxicity. Numerous other VDAs have since 
been developed with similar anti-tumour/toxicity profiles 
and many are under clinical evaluation. These include 
fosbretabulin, ombrabulin, crinobulin, and plinabulin. 
Although the vascular damage induced by VDAs can be severe 
and translates into a significant inhibition of tumour growth, 
it is never sufficient to induce tumour control, thus the 
potential of VDAs is not when used alone but when combined 
with conventional radiation or chemotherapy. Drug, timing, 
and sequencing are critical in such combinations. For 
radiation, pre-clinical studies performed using optimum 
conditions have shown a variety of different VDAs to be 
capable of significantly improving tumour response when the 
radiation is administered either as single treatments or in 
more clinically relevant fractionated and stereotactic 
schedules. Limited normal tissue studies, using both early 
and late responding endpoints, suggest no enhancement of 
radiation damage, thus a therapeutic benefit is observed. In 
this review we will briefly discuss the development of VDAs 
and the current status of both pre-clinical and clinical 
studies. 
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Purpose: In proton therapy, anatomical changes may cause 
considerable deterioration of the delivered dose 
distributions. Transmission-based treatment verification is 
generally not possible, making three-dimensional (3D) 
dosimetry a promising tool for verification of the delivered 
dose. However, solid state 3D detectors have shown 
significant problems related to linear-energy-transfer 
dependent quenching in particle beams – an under-response 
of the signal in the Bragg peak. A new deformable, silicone-
based, radiochromic 3D dosimeter has recently been 
developed by our group. The aim of this study was to perform 
the first proton beam experiments with this detector. Special 
attention was given to the quenching and dose-rate 
dependencies in general, relating these effects to the 
chemical composition of the dosimeter.  
